Teriparatide nasal spray

Drug Profile

Teriparatide nasal spray

Alternative Names: CHS-13340; Nasal rhPTH(1-34); Parathyroid hormone (1-34) - Chugai/Suntory; PTH (1-34) - Chugai/Suntory; SUN E 3001

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asubio Pharma
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 09 May 2008 Teriparatide nasal spray is still in phase II development for osteoporosis in Japan
  • 20 Mar 2008 Discontinued - Preclinical for Postmenopausal osteoporosis in World (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top